NASDAQ · PHAT
Healthcare · Biotechnology
$9.50
Up+$0.45 (+4.97%)
Updated Sep 8, 2026, 8:37 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
PHAT closed at $9.50 after 20 trading sessions, up 10.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $8.99 | $9.55 | $8.8901 | $9.50 | 1.24M |
| Sep 3, 2026 | $9.30 | $9.3113 | $8.984 | $9.05 | 663.06K |
| Sep 2, 2026 | $9.45 | $9.7296 | $9.05 | $9.26 | 932.65K |
| Sep 1, 2026 | $9.55 | $9.675 | $9.15 | $9.39 | 885.49K |
| Aug 31, 2026 | $9.17 | $9.695 | $9.0401 | $9.57 | 1.21M |
| Aug 28, 2026 | $8.89 | $9.305 | $8.7816 | $9.18 | 894.43K |
| Aug 27, 2026 | $8.77 | $8.99 | $8.545 | $8.94 | 1.05M |
| Aug 26, 2026 | $8.78 | $8.865 | $8.571 | $8.77 | 800.62K |
| Aug 25, 2026 | $8.75 | $8.94 | $8.64 | $8.80 | 748.61K |
| Aug 24, 2026 | $8.88 | $8.92 | $8.51 | $8.66 | 992.81K |
| Aug 21, 2026 | $8.63 | $8.896 | $8.59 | $8.87 | 979.41K |
| Aug 20, 2026 | $9.25 | $9.30 | $8.40 | $8.60 | 1.41M |
| Aug 19, 2026 | $9.42 | $9.70 | $9.31 | $9.32 | 781.95K |
| Aug 18, 2026 | $9.33 | $9.745 | $9.175 | $9.25 | 976.46K |
| Aug 17, 2026 | $9.47 | $9.57 | $9.215 | $9.28 | 1.14M |
| Aug 14, 2026 | $9.13 | $9.59 | $9.075 | $9.58 | 969.08K |
| Aug 13, 2026 | $9.25 | $9.3861 | $8.97 | $9.18 | 1.21M |
| Aug 12, 2026 | $8.51 | $9.185 | $8.47 | $9.17 | 2.08M |
| Aug 11, 2026 | $8.61 | $8.82 | $8.465 | $8.51 | 1.79M |
| Aug 10, 2026 | $8.44 | $8.89 | $8.405 | $8.57 | 2.15M |
The latest Smart Investors Daily articles mentioning PHAT.
PHAT research
Company profile and research snapshot.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Barclays | Overweight | — |
| Jul 31, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 31, 2026 | Guggenheim | Buy | — |
| Jul 30, 2026 | Needham | Buy | — |
| Jun 17, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 17, 2026
Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.
Yahoo · Aug 16, 2026
The latest update on Phathom Pharmaceuticals centers on a reset in valuation anchors, with fair value moving from US$23.70 to US$21.50 as analysts revisit their price targets. This change reflects a more cautious tone in recent research, where Q2 results, revised 2026 revenue guidance, and fresh views on Voquezna's commercial path are all feeding into how targets are being set. As you read on, you will see what is driving the evolving narrative and how to keep track of the key signals. Stay...
SeekingAlpha · Aug 1, 2026
2026-08-01. The following slide deck was published by Phathom Pharmaceuticals, Inc.
Benzinga · Jul 31, 2026
Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PHAT.
